10/18/01 4239-61375 SAS:jam

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mukherjee et al.

Application No.: Not yet assigned

Filed: Herewith

For: UTEROGLOBIN IN THE TREATMENT OF IGA

MEDIATED AUTOIMMUNE DISORDERS

Examiner: Not yet assigned

Date: October 18, 2001

Art Unit: Not yet assigned

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail, Label No. EL874429584US, on October 18, 2001: BOX PATENT APPLICATION, COMMISSIONER FOR

PATENTS, WASHINGTON, D.C. 20231.

William D. Noonan, M.D. Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

BOX PATENT APPLICATION COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

liam D. Noonan, M.D.

Registration No. 30,878

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

10/18/01 4239-61375 76921 SAS:jam

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mukherjee et al.

Application No.: Not yet assigned

Filed: Herewith

For: UTEROGLOBIN IN THE TREATMENT OF IGA

MEDIATED AUTOIMMUNE DISORDERS

Examiner: Not yet assigned

Date: October 18, 2001

Art Unit: Not yet assigned

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail, Label No. EL874429584US, on October 18, 2001: BOX PATENT APPLICATION, COMMISSIONER FOR

PATENTS, WASHINGTON, D.C. 20231.

Deouan Illum D William D. Noonan, M.D.

Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

BOX PATENT APPLICATION COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Man I Noonar

William D. Noonan, M.D. Registration No. 30,878

One World Trade Center, Suite 1600 121 S.W. Salmon Street

Portland, Oregon 97204 Telephone: (503) 226-7391 Facsimile: (503) 228-9446

C13 Rec'd PCT/PTO 1 8 OCT 2001

SAS:jam 10

0/17/2001	4239-61375	76909

INFORMATION DISCLOSURE STATEMENT			Docket: 4239-61375 App:							
			Applicant: Mukherjee et al.							
	BY APPLICANT			Filed: Herewith		Art Unit:				
U.S. PATENT DOCUMENTS										
Init.*		Number	Date		Name	Clas	ass Sub File		Filed	
-									_	
	FOREIGN PATENT DOCUMENTS									
		Number	Date		Country Class		s	Sub		
		WO 98/53846	12/03/1998	W	IPO					
	·		ОТН	ER 1	DOCUMENTS	<u> </u>				
		DeMayo, "Advantages and Pitfalls of Transgenic and Mutant Animals," American Journal of Kidney Diseases, Vol. 33, No. 3, pp. 598-600 (1999) Hildebrandt et al., "Familial Fibrillary Glomerulopathies: What is the Role of Fibronectin?" Advances in Nephrology, Vol. 28, pp. 429-437 (1998) Laing et al., "A polymorphism of the CC16 gene is associated with an increased risk of asthma," J. Med. Genet Vol. 35, pp. 463-467 (1998) Mathis, et al., "Isolates of Encephalitozoon cuniculi from farmed blue foxes (Alopex lagopus) from Norway differ from isolates from Swiss domestic rabbits (Oryctolagus cuniculus)," Parasitol Res., Vol. 82, pp. 727-730 (1996)								
	Nortier et al., "Proximal tubular injury in Chinese herb nephropathy: monitoring by neutral endopeptidase enzymuria," <i>Kidney International</i> , Vol. 51, No. 1, pp. 288-293 (1997) (Abstract) Szelestei, et al., "Association of Uteroglobin Polymorphism with Rate of Progression in Patients with IgA Nephropathy," <i>American Journal of Kidney Diseases</i> , Vol. 36, No. 3, pp. 468-473 (2000)									
EXAMINER:			DATE							
		nitial if considered			conformance with MPEP 6	09; drav	w lin	e throug	h cite if	

SAS:jam 10/16/2001 4239-61375 76909

INFORMATION DISCLOSURE		Docket: 4239-61375	App:			
STATEM		Applicant: Mukherjee et al.				
BY APPLIC	CANT	Filed: Herewith	Art Unit:			
OTHER DOCUMENTS						
Crystal Copoly	umane et al., "Bistable Electro-optical Fast Switching for Induced Smectic (Liquid rystalline Polymer/Liquid Crystals) and (Pseudo Liquid Crystalline opolymer/Liquid Crystals) Composite Systems," <i>Macromolecules</i> , Vol. 30, pp. 234-3241 (1997)					
		ssential in preventing immunoglol 5, No. 9, pp. 1018-1025 (1999)	oulin A nephropathy in			
EXAMINER: DATE						
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.						